Skip to main content

MoneyWorks4Me

NPPA slaps Novartis with Rs 300 crore penalty for over pricing of Voveran: Report

13 Oct 2014 Evaluate

National Pharmaceutical Pricing Authority (NPPA) has reportedly imposed a penalty of around Rs 300 crore on Novartis for over pricing its popular painkilling medicine Voveran. The company has also received a show cause notice to explain in two weeks why action should not be taken against it for overcharging.

Novartis India is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare.

Peers
Company Name CMP
Redington 356.35
Adani Enterprises 2731.05
Amrapali Industries 34.31
Maxgrow India 175.85
Rashi Peripheral 864.95
View more..